The reviewer makes a compelling argument that uPSA assays may in fact be useful for all patients after surgery rather than applied to patients who have developed a biochemical recurrence. The work by Slawin et al1 not only suggests that uPSA values represent a clinical tool to predict future BCR but also potentially identifies those patients who will continue to have a rising PSA beyond 0.2 ng/mL—men who nadir at a uPSA of 0.03 ng/mL or greater. Although this report is contradictory to an earlier...